Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

From Your Site Articles
Radiomer Therapeutics has launched under Fannin Partners with an undisclosed amount of seed funding. Photo via Getty Images

Early-stage cancer-fighting startup raises pre-seed, launches under Houston life science leader

ready to grow

Fannin Partners has done it again. The Houston-based life science development group behind medtech companies Procyrion and Allterum Therapeutics announced yesterday that it has launched Radiomer Therapeutics. With an undisclosed amount of pre-seed funding, Radiomer joins the $242 million-strong Fannin portfolio.

Radiomer uses Fannin’s proprietary Raptamer platform to target vectors and ligands for theranostic application. The cancer-fighting technology is a targeting agent that can address serious maladies including breast, lung, colorectal, prostate, and head and neck cancers.

And with Radiomer’s launch, Fannin is moving with its trademark aggressiveness. Lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in the first quarter of next year. Those will be closely followed by therapeutic programs.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, says in a press release. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

Varadhachary has operated Radiomer in stealth mode since its 2023 inception. However, Raptamer has been in the company’s portfolio since 2019. The new company has been using the platform to generate data with the rights to radiopharmaceutical applications for the past year.

“Our lead programs include Radiomers targeting both well-established and first-in-class cancer targets,” adds Dr. Phil Breitfeld, Radiomer’s chief medical officer. “Our imaging/dosimetry trials are designed to provide clinical evidence of tumor targeting and biodistribution information, positioning us to rapidly initiate a therapeutic program(s) if successful.”

For over a decade, Fannin has developed and supported promising life science innovations by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary said on the Houston Innovators Podcast earlier this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston bio-based materials startup breaks into footwear

cleaner shoes

A more sustainable shoe can’t be built on a single material swap. From the hard plastics hidden inside a heel to the material covering a sneaker’s upper, footwear is a collection of components—and each presents a different challenge for companies trying to move away from conventional, petroleum-based materials.

Houston-based Rheom Materials wants to change that equation. The biomaterials company has launched a sustainable footwear platform featuring two of its bio-based alternatives: Benree, a biodegradable plastic designed for hard internal components, and ShoraiDura, a durable leather alternative for footwear uppers.

“A shoe is not one material; it is multiple parts working together as a system. Substituting a single material has never moved the needle,” Rheom founder and CEO Zimri Hinshaw said in a news release. “Rheom wants to make it easier for brands to make a positive impact. By providing an assortment of bio-based materials, brands can change the system, not just a swatch of it.”

Benree is Rheom’s alternative to conventional hard plastics used in footwear construction. The company says it is a 100 percent USDA-certified bio-based, biodegradable material with performance comparable to acrylonitrile butadiene styrene (ABS), a widely used engineering plastic.

The material has passed SATRA testing for high-heel applications with Bared Footwear, an Australian footwear brand.

“At Bared, we're constantly on a journey to remove plastic from our shoes. At the same time, our brand won't compromise on quality for the end customer,” Millie Richards, Bared’s head of sustainability, added in the release. “From samples and testing, Rheom has proven to be solving both of those problems for us. We look forward to seeing how they develop as a company and would love to use them in our shoes.”

Rheom says it is also exploring Benree for additional internal components, including toe puffs and heel counters.

Rheom's Benree material was used for a high-heel prototype. Photo courtesy Rheom Materials

The company’s ShoraiDura material addresses another major part of shoe construction: the upper, which must withstand repeated flexing, friction and wear while maintaining its appearance.

Containing about 80 percent bio-based content, ShoraiDura is engineered as a durable leather alternative for footwear. Rheom says the material’s molecular structure is designed to deliver the strength and durability required for demanding applications.

To demonstrate how the material could be used in finished products, Rheom worked with a Los Angeles-based footwear manufacturer to create two prototypes: an athletic sneaker and a textured skater shoe, both featuring ShoraiDura uppers.

The two offerings reflect the company’s broader strategy. Rather than asking brands to evaluate a single material in isolation, Rheom is positioning its platform as a way to explore alternatives across different parts of footwear construction.

The next step is broader industry adoption. Benree’s testing with Bared Footwear and ShoraiDura’s footwear prototypes offer early examples of how the materials could be applied, while commercial use will depend on manufacturers’ evaluations and product-development decisions.

Rheom Materials is a Houston-based biomaterials company developing bio-based alternatives to petrochemical plastics. Its product portfolio includes Shorai, a leather alternative, and Benree, a hard plastic alternative.

The company debuted Shorai at the Houston Livestock Show and Rodeo in 2025 and showed a bio-based "leather" collection in Milan earlier this year. Read more here.

Houston's Rice University named the No. 1 best Texas college for 2027

We're No. 1

With early application season in full swing, a local university is racking up accolades on a new list of the 10 best Texas colleges for 2027.

Rice University topped the list as the No. 1 best university in Texas in WalletHub's annual "College & University Rankings" report, showing Houston students don't have to travel out of state to earn a top-notch degree.

WalletHub analyzed 738 colleges and universities in the U.S. using 30 relevant metrics, including factors like student-faculty ratios, graduation rates, and many more. Universities were ranked nationally, regionally, and across seven key dimensions: student selectivity; cost and financing; faculty resources; campus safety; campus experience; educational outcomes; and career outcomes.

Rice also ranked No. 2 in the regional comparison of best universities in the South, and appeared No. 11 nationwide.

Across the seven main categories, the university performed best for its faculty resources (No. 4), education outcomes (No. 11), and student selectivity (No. 16), and earned top-100 rankings for its career outcomes (No. 28) and campus experience (No. 58).

Rice only lagged behind in the national rankings for campus safety (No. 632) and cost and financing (No. 666), but neither category swayed the university's top-performing overall position.

Meanwhile, the University of Houston ranked 75th regionally and 339th nationally. UH's cost and financing rank among the top 200 nationally, landing 177th, and it ranked 284th for its campus safety.This is how the report ranked UH in the five remaining categories out of all 738 schools:
  • No. 306 – Career outcomes
  • No. 324 – Student selectivity
  • No. 343 – Education outcomes
  • No. 383 – Campus experience
  • No. 715 – Faculty resources
Four more local schools ranked among the best universities in the South: Houston Christian University (No. 204), Prairie View A&M University (No. 245), University of Houston-Downtown (No. 251), and Texas Southern University (No. 254).The Houston-area universities, including their graduate and online programs, have earned heaps of national and worldwide praise this year from prestigious educational reviewing authorities U.S. News & World Report and The Princeton Review. Rice University also topped Niche's list of the best Texas universities for 2027.

These are WalletHub's top 10 best colleges and universities in Texas for 2027:

  • No. 1 – Rice University
  • No. 2 – Trinity University
  • No. 3 – The University of Texas at Austin
  • No. 4 – Texas A&M University-College Station
  • No. 5 – Southwestern University
  • No. 6 – University of Dallas
  • No. 7 – Austin College
  • No. 8 – Texas Christian University
  • No. 9 – LeTourneau University
  • No. 10 – The University of Texas at Dallas
---

This article first appeared on CultureMap.com.

UH expands Medical Center footprint with $77M research facility

breaking ground

The University of Houston broke ground on a brand new $77.5 million Medical Research Building last week that will host clinical trials and a virtual reality behavioral health suite, among other laboratories. Designed by SmithGroup, it will be the second building on the UH Medical Center campus after the Fertitta College of Medicine opened in 2022.

“The Medical Research Building was designed to foster collaboration and discovery while creating a welcoming environment for students, researchers and the community,” Kalman Nagy, higher education studio design leader for SmithGroup, said in a news release. “As the second building on the University of Houston’s medical campus, we wanted to create a strong connection to the College of Medicine and the surrounding woodlands, with outdoor terraces, shared learning spaces and natural views that inspire interaction and innovation.”

Located just behind the Fertitta building at 5150 Medical Service Drive, the 57,000-square-foot building will house wet laboratories, computational research spaces and specialized facilities for clinical research. The virtual reality behavioral health suite will use immersive technology to deliver care through manufactured audio and visual environments. It’s part of the college’s vision for developing new medical advancements in the heart of Houston’s medical community. The groundbreaking comes on the heels of the launch of the university's cross-disciplinary academic venture, UH Health, this summer.

“This groundbreaking marks an important next step in the growth of the Fertitta College of Medicine and UH Health,” Dr. Jonathan McCullers, vice president for health affairs at UH, added in the release. “We are building the research capacity to match our ambitions—bringing together scientists, physicians and experts from across the University to accelerate discovery and turn promising ideas into solutions that improve people’s lives.”

UH’s journey to establish a significant presence alongside the University of Texas and Baylor in the Medical Center started in 2009 when it became an official full institutional member. The university launched its plans for the Fertitta building in 2013, and is pursuing Health Science Center designation from the Texas Legislature in the next year’s session.

“The research that will take place here will directly benefit our community,” UH President Renu Khator added. “Diseases do not recognize disciplinary silos, and neither should our research. This building will bring together experts from across UH to break down those barriers, work across disciplines and tackle some of our most complex health challenges.”

The building is slated to open in 2028.

View All Listings